- Synonyms
- TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Tumor Necrosis Factor Receptor Superfamily Member 11B
- Source
- Escherichia coli.
- Molecular Weight
- Approximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 173 amino acids.
- AA Sequence
- ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK
- Purity
- > 95 % by SDS-PAGE and HPLC analyses.
- Biological Activity
-
Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL).
- Physical Appearance
- Sterile Filtered White lyophilized (freeze-dried) powder.
- Formulation
- Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB,150 mM NaCl, pH 6.0.
- Endotoxin
- Less than 1 EU/μg of rHuOPG as determined by LAL method.
- Reconstitution
- We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.
- Stability & Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
- Usage
- This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
- SDS-PAGE
![](/cnuploadfiles/SDS/108-08 rHuOPG.png)
- Reference
- 1. Simonet WS, Lacey DL, Dunstan CR, et al. 1997. Cell. 89:309-19.
2. Schoppet M, Preissner KT, Hofbauer LC. 2002. Arterioscler Thromb Vasc Biol. 22:549-53.
3. Tsuda E, Goto M, Mochizuki S, et al. 1997. Biochem Biophys Res Commun. 234:137-42.
4. Luan X, Lu Q, Jiang Y, et al. 2012. J Immunol. 189:245-52.
- Background
- Osteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. OPG is a 401 a.a. basic glycoprotein which comprises 7 structural domains. It is either a 60 kDa monomer or a 120 kDa dimer linked by disulfide bridges. OPG acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro and may also play a role in preventing arterial calcification. OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Mature human OPG shares 86 %, 87 %, 92 %, 92 % and 88 % amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively.